Why Did Esperion Stock Soar 10.12%?

On March 26, 2025, Esperion's stock surged by 10.12% in pre-market trading, indicating a strong bullish sentiment among investors.

Esperion Therapeutics has been the subject of varied analyst ratings, with a mix of buy, hold, and sell recommendations. In the current month, the company has received 12 buy ratings, 0 hold ratings, and 5 sell ratings. This diverse range of opinions reflects the market's uncertainty about the company's future performance.

Historically, analyst price targets for Esperion have fluctuated significantly. For instance, in May 2021, Morgan Stanley reduced its price target from $30 to $22, while JMP Securities lowered its target from $191 to $111. These adjustments suggest that analysts are closely monitoring the company's developments and are willing to revise their expectations based on new information.